Novartis To Start Phase III Trial For Cancer Drug Everolimus
This article was originally published in PharmAsia News
Executive Summary
The Tokyo based subsidiary of Swiss drug maker Novartis Pharma plans to start final phase trial this summer for cancer drug everolimus (RAD001) to treat stomach cancer. A Phase II trial conducted in Japan showed positive results. Among 50 patients, 55 percent showed effectiveness in constraining cancerous growth and 45 percent showed effectiveness in shrinking tumor size. Although some patients developed side effects of stomatitic symptoms, the company viewed the results promising towards a product commercialization and decided to start the Phase III trial. (Click here for more - Japanese language
|
The Tokyo based subsidiary of Swiss drug maker Novartis Pharma plans to start final phase trial this summer for cancer drug everolimus (RAD001) to treat stomach cancer. A Phase II trial conducted in Japan showed positive results. Among 50 patients, 55 percent showed effectiveness in constraining cancerous growth and 45 percent showed effectiveness in shrinking tumor size. Although some patients developed side effects of stomatitic symptoms, the company viewed the results promising towards a product commercialization and decided to start the Phase III trial. (Click here for more - Japanese language) "Novartis To Start Final Phase Trial For Novel Stomach Cancer Drug" - Nikkei Kogyo News (1/18/09) |